Two Sigma Securities’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Two Sigma Securities’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397	Buy	57,539 +1,895	+3%	+$13	﹤0.01%	1649
2026 Q1	$556	Buy	55,644 +65	+0.1%	+$1	﹤0.01%	1582
2025 Q4	$784	Buy	+55,579	New	+$1.22K	﹤0.01%	1391

Other funds holding KTTAW

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Two Sigma Securities's KTTAW Position: Q2 2026 in Review

Two Sigma Securities increased its Pasithea Therapeutics Warrants (KTTAW) stake by 3.4% in Q2 2026, buying an estimated $13 and bringing the position to 57,539 shares worth $397. The position accounts for ﹤0.01% of the portfolio, ranked #1649.

Two Sigma Securities first reported a position in KTTAW in Q4 2025 and has held it in 3 quarters since. The position peaked at $784 in Q4 2025. 6 funds tracked by Wall St. Rank hold KTTAW as of Q2 2026.

Two Sigma Securities held 57,539 shares of Pasithea Therapeutics Warrants worth $397 as of Q2 2026.
Two Sigma Securities bought 1,895 Pasithea Therapeutics Warrants shares in Q2 2026, an estimated $13.
Pasithea Therapeutics Warrants made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1649 holding.
Two Sigma Securities first reported a position in Pasithea Therapeutics Warrants in Q4 2025 and has held it in 3 quarters since.
Two Sigma Securities's Pasithea Therapeutics Warrants position peaked at $784 in Q4 2025.
6 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.